BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 1584183)

  • 1. Positron emission tomography studies in parkinsonism.
    Eidelberg D
    Neurol Clin; 1992 May; 10(2):421-33. PubMed ID: 1584183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
    Piccini P; Turjanski N; Brooks DJ
    J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
    Kuriakose R; Stoessl AJ
    Prog Brain Res; 2010; 184():177-92. PubMed ID: 20887875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of PET in Parkinson's disease.
    Shinotoh H; Calne DB
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET and SPECT functional imaging studies in Parkinsonian syndromes: from the lesion to its consequences.
    Thobois S; Jahanshahi M; Pinto S; Frackowiak R; Limousin-Dowsey P
    Neuroimage; 2004 Sep; 23(1):1-16. PubMed ID: 15325346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Functional neuroimaging in movement disorders].
    Borbély K
    Orv Hetil; 2001 Oct; 142(43):2347-55. PubMed ID: 11760452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Is functional imaging useful in the clinical evaluation of Parkinson's disease?].
    Remy P
    Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S57-61. PubMed ID: 12773889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET and SPECT studies in Parkinson's disease.
    Brooks DJ
    Baillieres Clin Neurol; 1997 Apr; 6(1):69-87. PubMed ID: 9426869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor disturbance and brain functional imaging in Parkinson's disease.
    Brooks DJ
    Eur Neurol; 1997; 38 Suppl 2():26-32. PubMed ID: 9387800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DAT imaging in drug-induced and psychogenic parkinsonism.
    Tolosa E; Coelho M; Gallardo M
    Mov Disord; 2003 Oct; 18 Suppl 7():S28-33. PubMed ID: 14531043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography?
    Sawle GV
    Mov Disord; 1993 Jul; 8(3):271-7. PubMed ID: 8341290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments of dopaminergic imaging in Parkinson's disease.
    Varrone A; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Feb; 56(1):68-82. PubMed ID: 22460161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The metabolic topography of parkinsonism.
    Eidelberg D; Moeller JR; Dhawan V; Spetsieris P; Takikawa S; Ishikawa T; Chaly T; Robeson W; Margouleff D; Przedborski S
    J Cereb Blood Flow Metab; 1994 Sep; 14(5):783-801. PubMed ID: 8063874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
    Cordes M; Poewe W
    Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET.
    Shinotoh H; Hirayama K; Tateno Y
    Adv Neurol; 1993; 60():488-93. PubMed ID: 8420176
    [No Abstract]   [Full Text] [Related]  

  • 16. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia.
    Erritzoe D; Talbot P; Frankle WG; Abi-Dargham A
    Neuroimaging Clin N Am; 2003 Nov; 13(4):817-32. PubMed ID: 15024964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET measurements of dopaminergic pathways in the brain.
    Perlmutter JS; Moerlein SM
    Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome.
    Przedborski S; Goldman S; Levivier M; Giladi N; Bidaut LM; Hildebrand J; Stanus E; Labar D; Luxen A
    Mov Disord; 1993 Jul; 8(3):391-5. PubMed ID: 8341311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A positron emission tomography study on the role of nigral lesions in parkinsonism in patients with amyotrophic lateral sclerosis.
    Hideyama T; Momose T; Shimizu J; Tsuji S; Kwak S
    Arch Neurol; 2006 Dec; 63(12):1719-22. PubMed ID: 17172610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Positron-emission tomography in akinetic rigidity syndrome].
    Goldman S
    Rev Med Brux; 1995 Dec; 16(6):399-403. PubMed ID: 8570982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.